德谷门冬双胰岛素联合达格列净治疗血糖控制不佳2型糖尿病患者的临床疗效分析  

Clinical Efficacy of Insulin Degludec/Insulin Aspart Combined with Dapagliflozin in Inadequately Controlled Type 2 Diabetes Mellitus

作　　者：王素鑫 陈亚东 黄飞 Wang Suxin;Chen Yadong;Huang Fei(Department of Endocrinology,Sheyang County People's Hospital,Sheyang 224300,China;Department of Endocrinology,The First People's Hospital of Yancheng,Yancheng 224006,China)

机构地区：[1]射阳县人民医院内分泌科,江苏射阳224300 [2]盐城市第一人民医院内分泌科,江苏盐城224006

出　　处：《巴楚医学》2024年第3期91-95,共5页Bachu Medical Journal

基　　金：盐城市医学科技发展计划项目(No:YK2021002)。

摘　　要：目的:探讨德谷门冬双胰岛素联合达格列净治疗血糖控制不佳2型糖尿病患者的临床疗效。方法:选取2023年4月—2023年9月射阳县人民医院内分泌科收治的60例血糖控制不佳的2型糖尿病患者,随机分为门冬30组(给予门冬胰岛素30皮下注射联合口服达格列净治疗)和德谷门冬组(给予德谷门冬双胰岛素皮下注射联合口服达格列净治疗),每组各30例。比较两组患者早空腹、午餐前、晚餐前及晚睡前各时间点的血糖水平、平均血糖、血糖标准差、血糖波动幅度、血糖控制达标时间及胰岛素使用剂量。结果:两组患者血糖控制达标后,德谷门冬组患者的早空腹血糖[(6.17±1.71) mmol/L vs (6.78±0.23) mmol/L]、血糖标准差[(1.48±0.31) mmol/L vs (1.64±0.28) mmol/L]、血糖波动幅度[(3.04±0.82) mmol/L vs (3.88±0.67) mmol/L]及血糖控制达标时间[(6.00±2.00)天vs (7.13±1.66)天]均显著低于门冬30组患者(均P<0.05)。结论:德谷门冬双胰岛素联合达格列净对血糖控制不佳的2型糖尿病患者治疗效果较好,值得临床推广应用。Objective:To investigate the clinical efficacy of insulin degludec and insulin aspart combined with dapagliflozin in the treatment of type 2 diabetics with poor glycemic control.Methods:A total of 60 patients with type 2 diabetes mellitus and poor glycemic control admitted to the department of endocrinology in Sheyang County People's Hospital from April 2023 to September 2023 were enrolled.All of the patients were randomly divided into aspartate 30 group(subcutaneous injection of insulin aspartate 30 combined with oral dapagliflozin)and degludec aspartate group(subcutaneous injection of insulin degludec and insulin aspart combined with oral dapagliflozin),with 30 cases in each group.The blood glucose level,average blood glucose,standard deviation of blood glucose,fluctuation range of blood glucose,time to reach the standard of blood glucose control and insulin dose were compared between the two groups at the time of pre-breakfast,pre-lunch,pre-dinner and pre-bedtime.Results:After achieving glycemic control,the fasting blood glucose[(6.17±1.71)mmol/L vs(6.78±0.23)mmol/L],blood glucose standard deviation[(1.48±0.31)mmol/L vs(1.64±0.28)mmol/L]and blood glucose fluctuation range[(3.04±0.82)mmol/L vs(3.88±0.67)mmol/L]and time to achieve glycemic control[(6.00±2.00)days vs(7.13±1.66)days]of degludec aspartate group were significantly lower than those in aspartate 30 group(all P<0.05).Conclusion:Insulin degludec and insulin aspart combined with dapagliflozin has a good therapeutic effect on type 2 diabetics with inadequate glycemic control,and it is worthy of clinical application.

关 键 词：德谷门冬双胰岛素 门冬胰岛素30 达格列净 2型糖尿病 血糖控制不佳 

分 类 号：R587.1[医药卫生—内分泌]